Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 7/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 14/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.61 |
| ▸ | LPAR4 | Q99677 | 6/20 | 0.61 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258136 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7820593 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL28064781 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258118 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL12621099 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7829804 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258161 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258032 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258094 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL250888 | 0.98 | LPAR5 (0.97) | LPAR5LPAR1LPAR3LPAR2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195547-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | UNIV VANDERBILT (US) | 2025-06-19 | — | — | US | claimed |
| WO-2023205635-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | VANDERBILT UNIVERSITY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20250195547-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | UNIV VANDERBILT (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2023205635-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | VANDERBILT UNIVERSITY (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195547-A1 | COMPOSITIONS AND METHODS OF TREATMENT FOR CONGENITAL DIARRHEAL DISORDER | LPAR5, MYO3B, MYO3A | LPAR5 1/4885LPAR1 9/4885LPAR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.